Pregnenolone, a cholesterol metabolite, induces glioma cell apoptosis via activating extrinsic and intrinsic apoptotic pathways

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 645-650

  Xiao, Xiao ^a   Chen, Lijun ^a   Ouyang, Ying ^b   Zhu, Wenbo ^a   Qiu, Pengxin ^a   Su, Xinwen ^a   Dou, Yunling ^c   Tang, Lipeng ^a   Yan, Min ^a   Zhang, Haipeng ^a   Yang, Xiaoxiao ^a   Xu, Dong ^a   Yan, Guangmei ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Glioma; Pregnenolone

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PREGNENOLONE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; TUBULIN;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VIABILITY; CYTOTOXICITY ASSAY; DOWN REGULATION; ENZYME ACTIVITY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; RAT; UPREGULATION; WESTERN BLOTTING;

EID: 84902304945     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2147     Document Type: Article

References (37)

1. Dolecek TA, Propp JM, Stroup NE and Kruchko C: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 14 Suppl 5: v1-v49, 2012.
2. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
3. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773, 2009.
4. Rousseau A, Mokhtari K and Duyckaerts C: The 2007 WHO classification of tumors of the central nervous system-what has changed? Curr Opin Neurol 21: 720-727, 2008.
5. Mutter N and Stupp R: Temozolomide: a milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6: 1187-1204, 2006.
6. Chamberlain MC: Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10: 1537-1544, 2010.
7. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
8. Wirth T, Samaranayake H, Pikkarainen J, Määttä AM and Ylä-Herttuala S: Clinical trials for glioblastoma multiforme using adenoviral vectors. Curr Opin Mol Ther 11: 485-492, 2009.
9. Gorski J and Gannon F: Current models of steroid hormone action: a critique. Annu Rev Physiol 38: 425-450, 1976.
10. Stocco DM: StAR protein and the regulation of steroid hormone biosynthesis. Annu Rev Physiol 63: 193-213, 2001.
11. Falkenstein E, Tillmann HC, Christ M, Feuring M and Wehling M: Multiple actions of steroid hormones-A focus on rapid, nongenomic effects. Pharmacol Rev 52: 513-555, 2000.
12. Rupprecht R: The neuropsychopharmacological potential of neuroactive steroids. J Psychiatr Res 31: 297-314, 1997.
13. LaVallee TM, Zhan XH, Johnson MS, et al: 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63: 468-475, 2003.
14. LaVallee TM, Zhang XGH, Herbstritt CJ, Kough EC, Green SJ and Pribluda VS: 2-methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res 62: 3691-3697, 2002.
15. Lin HL, Liu TY, Wu CW and Chi CW: 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2){combining long solidus overlay}M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 92: 500-509, 2001.
16. Kirches E and Warich-Kirches M: 2-methoxyestradiol as a potential cytostatic drug in gliomas? Anticancer Agents Med Chem 9: 55-65, 2009.
17. Tang YC, Williams BR, Siegel JJ and Amon A: Identification of aneuploidy-selective antiproliferation compounds. Cell 144: 499-512, 2011.
18. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006.
19. Chandrasekar B, Vemula K, Surabhi RM, et al: Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem 279: 20221-20233, 2004.
20. Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798, 2008.
21. Degterev A, Boyce M and Yuan J: A decade of caspases. Oncogene 22: 8543-8567, 2003.
22. Dubrovsky BO: Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 29: 169-192, 2005.
23. Mellon SH and Griffin LD: Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 13: 35-43, 2002.
24. Marx CE, Bradford DW, Hamer RM, et al: Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 191: 78-90, 2011.
25. Tsutsui K, Matsunaga M and Ukena K: Biosynthesis and biological actions of neurosteroids in the avian brain. Avian Poultry Biol Rev 14: 63-78, 2003.
26. Lacroix C, Fiet J, Benais JP, et al: Simultaneous radioimmunoassay of progesterone, androst-4-enedione, pregnenolone, dehydroepiandrosterone and 17-hydroxyprogesterone in specific regions of human brain. J Steroid Biochem 28: 317-325, 1987.
27. Liu S, Ishikawa H, Li FJ, et al: Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma. Cancer Res 65: 2269-2276, 2005.
28. Ishimaru C, Yonezawa Y, Kuriyama I, Nishida M, Yoshida H and Mizushina Y: Inhibitory effects of cholesterol derivatives on DNA polymerase and topoisomerase activities, and human cancer cell growth. Lipids 43: 373-382, 2008.
29. Girón RA, Montaño LF, Escobar ML, López-Marure R: Dehydroepiandrosterone inhibits the proliferation and induces the death of HPV-positive and HPV-negative cervical cancer cells through an androgen-and estrogen-receptor independent mechanism. FEBS J 276: 5598-5609, 2009.
30. Simons K and Ikonen E: How cells handle cholesterol. Science 290: 1721-1726, 2000.
31. Lingwood D and Simons K: Lipid rafts as a membrane-organizing principle. Science 327: 46-50, 2010.
32. Anderson RG and Jacobson K: A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 296: 1821-1825, 2002.
33. Zhuang L, Kim J, Adam RM, Solomon KR and Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115: 959-968, 2005.
34. Shieh PC, Tsao CW, Li JS, et al: Role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the action of ginsenoside Rh2 against beta-amyloid-induced inhibition of rat brain astrocytes. Neurosci Lett 434: 1-5, 2008.
35. Yi JS, Choo HJ, Cho BR, et al: Ginsenoside Rh2 induces ligand-independent Fas activation via lipid raft disruption. Biochem Biophys Res Commun 385: 154-159, 2009.
36. Jansen M, Pietiaïnen VM, Pölönen H, et al: Cholesterol substitution increases the structural heterogeneity of caveolae. J Biol Chem 283: 14610-14618, 2008.
37. Patra SK: Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 1785: 182-206, 2008.